Surgery or Biologic for Nasal Polyps? A Close Look at the Evidence
October 12, 2023
October 12, 2024
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and and Sanofi.
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
The intended audience for this program is ENTs, allergists, immunologists, specialty nurse practitioners and PAs, and other clinicians involved in the management of patients with nasal polyps.
As management strategies for nasal polyps (NPs) have evolved, patients whose NPs do not respond to initial treatment, who are ineligible for systemic corticosteroids, or whose NPs recur after initial surgery often undergo repeated surgeries, with high associated costs and complication risks. Clinicians—including ear, nose, and throat specialists (ENTs) and allergists—need to be aware of the latest strategies to personalize NP care and establish personalized treatment plans with the lowest risk of recurrence, toward improving patients’ overall quality of life, including their ability to breath and smell.
Join an expert panel of ENTs to explore the underlying pathways that lead to NPs and drive recurrent disease and treatment resistance. Panelists will also discuss the burdens faced by patients with NPs and evidence supporting the efficacy and safety of biologic agents for the treatment of refractory and recurrent NPs.
Do you have patients with NPs who could benefit from education on biologic treatment options? Direct your patients to MedLive.com to access the activity, “Making Your Voice Heard: Could Your Nasal Polyps Benefit from a Biologic Medicine?”
After completing this activity, the participant should be better able to:
- Describe the inflammatory relationships between NPs and common T2-driven comorbidities
- Discuss safety, efficacy, and impacts on bothersome symptoms of current targeted therapies for patients with moderate-to-severe CRSwNP
- Review patient-specific factors that help predict NP recurrence after standard treatment, including surgery
Stella Lee, MD
Director of the Brigham Sinus Center
Brigham and Women's Hospital
Noam Cohen, MD, PhD
Professor of Otorhinolaryngology – Head and Neck Surgery
Perelman School of Medicine at The University of Pennsylvania
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Instruction for Participaton and Credit:
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instruction to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at [email protected].
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”